MA37749B1 - Vaccins contre les virus réassortis de la fièvre catarrhale et de la peste équine - Google Patents

Vaccins contre les virus réassortis de la fièvre catarrhale et de la peste équine

Info

Publication number
MA37749B1
MA37749B1 MA37749A MA37749A MA37749B1 MA 37749 B1 MA37749 B1 MA 37749B1 MA 37749 A MA37749 A MA 37749A MA 37749 A MA37749 A MA 37749A MA 37749 B1 MA37749 B1 MA 37749B1
Authority
MA
Morocco
Prior art keywords
african horse
horse sickness
bluetongue
vaccines against
sickness virus
Prior art date
Application number
MA37749A
Other languages
English (en)
Other versions
MA37749A1 (fr
Inventor
Massimo Palmarini
Pascal Hudelet
Jean-Christophe Audonnet
Sandro Filipe Nunes
Original Assignee
Merial Ltd
Univ Glasgow Court
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merial Ltd, Univ Glasgow Court filed Critical Merial Ltd
Publication of MA37749A1 publication Critical patent/MA37749A1/fr
Publication of MA37749B1 publication Critical patent/MA37749B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12111—Orbivirus, e.g. bluetongue virus
    • C12N2720/12121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12111—Orbivirus, e.g. bluetongue virus
    • C12N2720/12134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12111—Orbivirus, e.g. bluetongue virus
    • C12N2720/12171—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne des vaccins ou des compositions contre la fièvre catarrhale (btv) et la peste équine (ashv), des procédés de production de vecteurs recombinés des virus réassortis de la fièvre catarrhale et de la peste équine, et des procédés de vaccination contre la fièvre catarrhale et la peste équine.
MA37749A 2012-06-13 2013-06-13 Vaccins contre les virus réassortis de la fièvre catarrhale et de la peste équine MA37749B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261659198P 2012-06-13 2012-06-13
PCT/US2013/045667 WO2013188673A2 (fr) 2012-06-13 2013-06-13 Vaccins contre les virus réassortis de la fièvre catarrhale et de la peste équine

Publications (2)

Publication Number Publication Date
MA37749A1 MA37749A1 (fr) 2016-08-31
MA37749B1 true MA37749B1 (fr) 2017-05-31

Family

ID=49237584

Family Applications (1)

Application Number Title Priority Date Filing Date
MA37749A MA37749B1 (fr) 2012-06-13 2013-06-13 Vaccins contre les virus réassortis de la fièvre catarrhale et de la peste équine

Country Status (17)

Country Link
US (1) US10801039B2 (fr)
EP (1) EP2861248B1 (fr)
JP (1) JP6347257B2 (fr)
KR (1) KR102136437B1 (fr)
CN (2) CN110628822A (fr)
AU (2) AU2013274191B2 (fr)
BR (1) BR112014031133B1 (fr)
CA (1) CA2876196C (fr)
ES (1) ES2664069T3 (fr)
IL (1) IL236148B (fr)
MA (1) MA37749B1 (fr)
MX (1) MX364875B (fr)
NZ (1) NZ703297A (fr)
RU (1) RU2656187C2 (fr)
TN (1) TN2014000518A1 (fr)
WO (1) WO2013188673A2 (fr)
ZA (1) ZA201409124B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA44722A (fr) 2016-04-19 2019-02-27 Csir Vlp d'orbivirus chimériques produites par des plantes
CN109312351B9 (zh) * 2016-04-26 2020-10-23 伦敦卫生及热带医学学院 呼肠孤病毒科疫苗
WO2018103038A1 (fr) * 2016-12-08 2018-06-14 拜西欧斯（北京）生物技术有限公司 Conjugué et son utilisation
CN109897092B (zh) * 2019-04-02 2019-11-19 深圳海关动植物检验检疫技术中心 一种蓝舌病病毒非结构蛋白ns3的可溶制备方法
CN110016466B (zh) * 2019-05-21 2022-09-13 云南省畜牧兽医科学院 特异性检测蓝舌病病毒的单抗及其杂交瘤细胞株和应用
CN110257560B (zh) * 2019-07-23 2023-06-27 深圳海关动植物检验检疫技术中心 一种用于蓝舌病病毒8型检测的试剂、检测方法及应用
CN112375848A (zh) * 2020-12-11 2021-02-19 云南省畜牧兽医科学院 一种蓝舌病病毒血清型鉴定的RT-qPCR检测试剂盒和方法
CN116024183B (zh) * 2023-02-15 2023-10-31 中国农业科学院兰州兽医研究所 一种用于荧光染色的重组蓝舌病毒及其构建方法
CN120271699B (zh) * 2025-04-10 2026-03-31 中国农业科学院兰州兽医研究所(中国动物卫生与流行病学中心兰州分中心) 一株特异识别蓝舌病毒vp5蛋白的单克隆抗体

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2909462A (en) 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
US5505941A (en) 1981-12-24 1996-04-09 Health Research, Inc. Recombinant avipox virus and method to induce an immune response
CA1247080A (fr) 1983-03-08 1988-12-20 Commonwealth Serum Laboratories Commission Sequences d'acides amines ayant une activite antigenique
DE3584341D1 (de) 1984-08-24 1991-11-14 Upjohn Co Rekombinante dna-verbindungen und expression von polypeptiden wie tpa.
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
US4963481A (en) 1985-12-18 1990-10-16 Genetics Institute Inc Promoter system
GB2197321B (en) 1986-09-12 1990-10-03 Genentech Inc Method and vectors for obtaining continuous production of heterologous protein in a eukaryotic host cell line
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
DE3743138A1 (de) 1987-12-18 1989-09-14 Mayr Christian Gmbh & Co Kg Schleifringlose, elektromagnetische ueberlastkupplung
WO1992015672A1 (fr) 1991-03-07 1992-09-17 Virogenetics Corporation Souche de vaccin mise au point par genie genetique
EP0826063A1 (fr) 1995-04-25 1998-03-04 Vical Incorporated Formulations en ampoule unidose de complexes adn/lipides
US5846946A (en) 1996-06-14 1998-12-08 Pasteur Merieux Serums Et Vaccins Compositions and methods for administering Borrelia DNA
FR2751226B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies du cheval
FR2751229B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique notamment contre la pathologie respiratoire des bovins
FR2751227B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies canines, notamment les pathologies respiratoires et digestives
FR2751224B1 (fr) 1996-07-19 1998-11-20 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies respiratoires et de reproduction des porcs
FR2751225B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique aviaire
FR2751228B1 (fr) 1996-07-19 1998-11-20 Rhone Merieux Vaccin polynucleotidique bovin pour voie intradermique
JP4111403B2 (ja) 1996-10-11 2008-07-02 ザ リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア 免疫刺激ポリヌクレオチド／免疫調節分子複合体
DE69826124T3 (de) 1997-06-30 2007-10-11 Institut Gustave Roussy Verabreichung der nukleinsäure in den quergestreiften muskel
FR2778858B1 (fr) 1998-05-20 2000-06-16 Oreal Emulsion e/h/e stable et son utilisation comme composition cosmetique et/ou dermatologique
FR2801607B1 (fr) 1999-11-26 2001-12-28 Merial Sas Pneumovirus du canard et vaccins correspondants
US6852705B2 (en) 2000-01-21 2005-02-08 Merial DNA vaccines for farm animals, in particular bovines and porcines
ATE392905T1 (de) 2003-07-24 2008-05-15 Merial Ltd Vakzin-formulierungen mit einer öl-in-wasser- emulsion
US7862821B2 (en) 2006-06-01 2011-01-04 Merial Limited Recombinant vaccine against bluetongue virus
EP2062594A1 (fr) * 2007-11-21 2009-05-27 Wyeth Farma, S.A. Vaccin de la fièvre catarrhale du mouton et compositions immunogènes, procédé d'utilisation et son procédé de production
WO2009068870A1 (fr) * 2007-11-26 2009-06-04 London School Of Hygiene & Tropical Medicine Procédé de fabrication d'une souche virale vaccinale d'un virus de la famille des reoviridae

Also Published As

Publication number Publication date
MX364875B (es) 2019-05-09
BR112014031133B1 (pt) 2023-02-07
ZA201409124B (en) 2017-05-31
TN2014000518A1 (en) 2016-03-30
RU2656187C2 (ru) 2018-05-31
HK1209326A1 (en) 2016-04-01
ES2664069T3 (es) 2018-04-18
IL236148A0 (en) 2015-01-29
EP2861248A2 (fr) 2015-04-22
WO2013188673A2 (fr) 2013-12-19
WO2013188673A3 (fr) 2014-03-27
KR102136437B1 (ko) 2020-07-21
KR20150036057A (ko) 2015-04-07
US10801039B2 (en) 2020-10-13
NZ703297A (en) 2016-04-29
JP6347257B2 (ja) 2018-06-27
CN104582724A (zh) 2015-04-29
AU2013274191B2 (en) 2016-09-22
RU2015100269A (ru) 2016-08-10
AU2013274191A1 (en) 2015-01-22
JP2015525076A (ja) 2015-09-03
CA2876196C (fr) 2021-09-21
US20130337010A1 (en) 2013-12-19
MX2014015311A (es) 2016-04-04
IL236148B (en) 2019-05-30
BR112014031133A2 (fr) 2017-08-15
MA37749A1 (fr) 2016-08-31
AU2016235036A1 (en) 2016-10-27
CA2876196A1 (fr) 2013-12-19
CN110628822A (zh) 2019-12-31
EP2861248B1 (fr) 2017-11-15

Similar Documents

Publication Publication Date Title
MX2018010483A (es) Inmunogenos para vacunacion contra vih.
MX2017001406A (es) Agentes a base de flagelina y usos de los mismos, incluyendo vacunación efectiva.
EA201591287A1 (ru) Вакцины, содержащие стабилизированные тримеры оболочки вируса иммунодефицита человека, и способы их применения
GB0917002D0 (en) Improved shigella blebs
EA201391109A1 (ru) Молекулы нуклеиновой кислоты, кодирующие новые антигены герпеса, вакцина, включающая их, и способы их использования
EA201391515A1 (ru) Инактивированная вакцина вируса денге
IN2014CN00688A (fr)
TR201905619T4 (tr) Alerji aşısı olarak peptit taşıyıcı füzyon proteinleri.
WO2013106834A3 (fr) Peptides wt-1 immunogènes et leurs procédés d'utilisation
EA201290876A1 (ru) Композиции индуцированных дендритных клеток и их использование
MX2019003716A (es) Formulaciones farmaceuticas de anticuerpos tnf-alfa.
EA201001491A1 (ru) Репликационно-дефектные вакцины и вакцинные векторы против флавивирусов
EA201391240A1 (ru) Слитые белки и комбинированные вакцины, содержащие белок е и пилин а haemophilus influenza
MA37749A1 (fr) Vaccins contre les virus réassortis de la fièvre catarrhale et de la peste équine
EA201500383A1 (ru) Производные 1,2,4-триазина для лечения вирусных инфекций
MX2014006630A (es) Vacuna a base toxina clostridium difficile.
MX387400B (es) Células de mamífero que expresan antígenos de citomegalovirus.
NZ702146A (en) Peptides derived from viral proteins for use as immunogens and dosage reactants
MX366178B (es) Proteinas de btnl3, acidos nucleicos, y anticuerpos y los usos de los mismos.
AR128395A2 (es) Péptidos novedosos capaces de inducir la formación de anticuerpos contra pcsk9
GB201017519D0 (en) Vaccines
WO2013177593A3 (fr) Identification d'antigènes phosphopeptidiques de cmh de classe i du cancer du sein à l'aide d'une technologie shla et de stratégies d'enrichissement complémentaires
MX2015013304A (es) Vacunas de nucleoproteina de la influenza.
PH12017501100B1 (en) Recombinant swinepox virus and vaccines
MX2019007924A (es) Vacunas contra la influenza.